# Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women

> **NCT01266213** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 147 (estimated)

## Conditions studied

- Metastatic Breast Cancer
- Estrogen Receptor Positive Tumor
- Breast Cancer Nos Premenopausal

## Interventions

- **DRUG:** Fulvestrant plus Goserelin
- **DRUG:** Anastrozole plus Goserelin
- **DRUG:** Goserelin

## Key facts

- **NCT ID:** NCT01266213
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-12
- **Primary completion:** 2018-06
- **Final completion:** 2019-12
- **Target enrollment:** 147 (ESTIMATED)
- **Last updated:** 2017-05-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01266213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01266213, "Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01266213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*